Med2Date — Clinical Guidelines
Home Oncology Oncological Emergencies

Oncological Emergencies

Last updated 31 May 2026 · Oncology clinical guideline

📋 Key Information Summary

📋
  • Oncological emergencies — spinal cord compression (SCC), superior vena cava (SVC) syndrome, tumour lysis syndrome (TLS), and febrile neutropenia (FN) — require rapid recognition, early specialist involvement, and time-critical intervention to reduce morbidity and mortality.
  • SCC: New back pain in a cancer patient is malignant spinal cord compression until proven otherwise. Urgent MRI spine (within 24 h ideally) and early dexamethasone 16 mg IV stat are essential. Refer urgently to radiation oncology and/or neurosurgery.
  • SVC syndrome: Caused most commonly by lung cancer and lymphoma. CT chest with contrast confirms diagnosis. Stenting may relieve symptoms rapidly. Anticoagulation if indwelling catheter-related thrombus is identified.
  • TLS: Prophylaxis (IV hydration + allopurinol) is indicated for all intermediate- and high-risk patients. Rasburicase (PBS Authority Required) is first-line for established high-risk TLS. Monitor urate, phosphate, potassium, calcium, creatinine at 0, 6, 12, 24 h.
  • Febrile neutropenia: Fever ≥ 38.0 °C on a single reading or ≥ 38.3 °C sustained + neutrophils < 0.5 × 10⁹/L. Administer piperacillin-tazobactam (Tazocin®) IV within 60 minutes of presentation. Risk-stratify with MASCC score.
  • Time-critical nature: Each emergency has a distinct window for optimal intervention — SCC ideally < 24 h to surgery/radiotherapy; TLS prophylaxis pre-chemotherapy; FN antibiotics within 60 min.
  • Dexamethasone is used in both SCC (16 mg IV stat then 8 mg BD) and SVC syndrome (4–16 mg IV/PO) to reduce tumour-related oedema and inflammation.
  • Multi-disciplinary coordination between oncology, emergency medicine, radiation oncology, neurosurgery, nephrology, and haematology is critical for all four emergencies.
  • MASCC risk-index score ≥ 21 identifies low-risk febrile neutropenia patients potentially suitable for oral antibiotic therapy in a supervised ambulatory setting.
  • TLS metabolic derangements — hyperkalaemia, hyperphosphataemia, hyperuricaemia, hypocalcaemia — can cause fatal arrhythmias and acute kidney injury if untreated.
  • Aboriginal and Torres Strait Islander patients present with higher-stage malignancy at diagnosis and experience greater barriers to timely emergency oncological care — early liaison with Indigenous health workers is essential.
  • Advanced care planning and goals-of-care discussions should be integrated into emergency management where prognosis permits.

Introduction & Australian Epidemiology

Oncological emergencies are acute, life-threatening conditions arising directly from a malignancy, its complications, or anti-cancer therapy. In Australia, cancer accounts for approximately 150,000 new diagnoses annually, and roughly 50,000 deaths per year — making it the leading cause of premature mortality. A significant proportion of cancer patients will present to emergency departments with an oncological crisis at some point during their disease trajectory.

The four most common oncological emergencies encountered in Australian practice are malignant spinal cord compression, superior vena cava syndrome, tumour lysis syndrome, and febrile neutropenia. Each demands rapid clinical recognition, systematic investigation, and time-sensitive therapeutic intervention. Delay in diagnosis and treatment is associated with significantly worse outcomes — including permanent neurological deficit in spinal cord compression, fatal arrhythmia in tumour lysis syndrome, and septic death in febrile neutropenia.

The Australian Institute of Health and Welfare (AIHW) reports that cancer-related emergency presentations have risen by approximately 15% over the past decade, driven by expanding treatment options, an ageing population, and increased use of myelosuppressive and immunomodulatory regimens. Aboriginal and Torres Strait Islander Australians experience a 14% higher cancer mortality rate compared to non-Indigenous Australians, with later-stage presentation and barriers to timely specialist care contributing to poorer outcomes.

This guideline provides a structured, evidence-based approach to the recognition, investigation, and management of each emergency, aligned with Australian therapeutic standards, PBS-listed medications, and contemporary multidisciplinary practice.

Emergency Key Mechanism Most Common Cancer Time to Intervention
Spinal Cord Compression Epidural metastasis compressing the thecal sac Lung, breast, prostate, myeloma < 24 h for surgery/radiotherapy
Superior Vena Cava Syndrome External compression or thrombosis of SVC Lung cancer (NSCLC), lymphoma Stenting/emergent chemo within hours–days
Tumour Lysis Syndrome Massive cell lysis releasing intracellular contents Haematological — AML, ALL, high-grade lymphoma Prophylaxis pre-chemo; Rx within 6 h of lab derangement
Febrile Neutropenia Immune compromise + infection All — particularly post-chemotherapy haematological malignancies Antibiotics within 60 min

Spinal Cord Compression

🚨
Clinical red flag: Any new or progressive back pain in a patient with known or suspected malignancy must be considered malignant spinal cord compression (MSCC) until proven otherwise. Neurological deficit at presentation implies a poorer prognosis — early diagnosis before motor signs is the goal.

Epidemiology & Aetiology

MSCC occurs in 5–10% of patients with cancer and is the presenting feature of malignancy in approximately 20% of cases. In Australia, the most common primary tumours causing MSCC are lung cancer (25–30%), breast cancer (15–20%), prostate cancer (10–15%), and multiple myeloma (10%). The thoracic spine is the most frequently affected site (60–70%), followed by lumbosacral (20–30%) and cervical regions (5–10%).

Pathophysiology

Metastatic deposits extend into the epidural space via the vertebral body (most commonly) or the pedicles. Progressive expansion leads to direct compression of the spinal cord and/or cauda equina, venous congestion, and local ischaemia. Oedema extends both rostral and caudal to the level of compression, creating a zone of potentially reversible injury surrounding a core of irreversible infarction. Dexamethasone reduces this perilesional oedema.

Clinical Presentation & Diagnostic Criteria

  • Back pain — present in > 95% of cases; typically localised, worse when supine, nocturnal, and progressive over days to weeks.
  • Motor weakness — ranging from difficulty walking to paraplegia/quadriplegia.
  • Sensory loss — a sensory level may be identifiable on examination.
  • Autonomic dysfunction — urinary retention or incontinence, faecal incontinence, constipation.
  • Lhermitte sign — electric-shock sensation radiating down the spine on neck flexion.

Investigations

Essential
MRI whole spine (with gadolinium)
Gold standard. Identifies level(s) of compression, extent of epidural disease, and vertebral collapse. Should be performed within 24 h of clinical suspicion. Available at all tertiary centres and most regional centres in Australia; tele-radiology enables urgent reporting.
Available
CT spine (if MRI contraindicated)
Can identify bony destruction and vertebral collapse but inferior for soft-tissue assessment of the epidural space. Useful when MRI is unavailable or contraindicated (e.g., incompatible pacemaker).
Available
CT chest/abdomen/pelvis
Staging and primary tumour identification if malignancy is not yet diagnosed.
Available
Bone scan (Tc-99m)
May show additional skeletal metastases. Less sensitive than MRI for epidural disease. MBS item 61306.
Available
Bloods: FBC, EUC, LFTs, calcium, LDH, tumour markers, Bence-Jones protein
Baseline and to identify primary tumour. Elevated ALP and calcium suggest skeletal metastatic burden.

Immediate Management

💊
Dexamethasone
Dexamethasone Sodium Phosphate (DBL) · Corticosteroid
Adult dose (immediate) 16 mg IV bolon as soon as MSCC suspected, then 8 mg IV/PO BD
Taper Reduce by 2 mg every 3–4 days post radiotherapy/surgery; total course 10–14 days
Route IV bolus → PO when able to swallow
Renal adjustment Nil required
Caution Add PPI (omeprazole 20 mg PO daily) for gastroprotection. Monitor BGL in diabetics.
PBS status ✔ PBS General Benefit

Definitive Management

1
Urgent referral
Refer to radiation oncology AND neurosurgery/orthopaedic spine team immediately upon MRI confirmation. Patients with radiotherapy-responsive tumours (breast, prostate, myeloma, lymphoma) are typically managed with emergency radiotherapy. Surgical decompression (separation surgery) may be considered for mechanical instability, radio-resistant tumours, or progressive neurological deterioration despite radiotherapy.
2
Radiotherapy
Typically 30 Gy in 10 fractions or 8 Gy in 1 fraction (palliative). Should commence within 24 h if possible. Coordination with regional cancer centres (Peter MacCallum, Chris O'Brien Lifehouse, Royal Adelaide Hospital Cancer Centre) for transfer.
3
Surgical decompression
Posterior decompression ± instrumented stabilisation for patients with spinal instability, posterior element disease, or radio-resistant histology (e.g., renal cell carcinoma). Separation surgery aims to create a 3–5 mm circumferential margin for post-operative radiotherapy.
⚠️
Ambulation is the strongest predictor of outcome. Patients who can walk at presentation have an 80% chance of maintaining ambulation with treatment; those who are paraplegic have only a 5–10% chance of regaining the ability to walk. Act on early symptoms — do not wait for motor signs.

Superior Vena Cava Syndrome

Epidemiology & Aetiology

Superior vena cava (SVC) syndrome results from obstruction or compression of the SVC, impairing venous return from the head, neck, and upper extremities. Malignant causes account for approximately 85–95% of cases in adult practice. In Australia, non-small cell lung cancer (NSCLC) is the most common cause (60–75%), followed by lymphoma (10–15%) and small cell lung cancer (5–10%). Increasingly, SVC syndrome is associated with indwelling central venous catheters, pacemaker wires, and mediastinal fibrosis.

Clinical Presentation & Diagnostic Criteria

  • Facial swelling and plethora — worse in the morning and with bending forward.
  • Distended neck veins and superficial thoracic venous collaterals.
  • Dyspnoea — may be positional; stridor in severe cases due to laryngeal oedema.
  • Cough, hoarseness, dysphagia — from associated mediastinal mass effect.
  • Central nervous system symptoms — headache (typically worse on waking), visual disturbance, confusion, syncope in severe obstruction.
  • Upper extremity oedema.

Severity grading: Mild (facial/neck swelling only) → Moderate (dyspnoea on exertion, stridor, mild oedema) → Severe (rest dyspnoea, laryngeal oedema, cerebral oedema with obtundation).

🚨
Emergency airway compromise: Stridor at rest, severe facial/upper airway oedema, or altered consciousness require immediate critical care involvement. Endotracheal intubation may be technically difficult due to laryngeal oedema — experienced anaesthetic assistance is essential.

Investigations

Essential
CT chest with IV contrast
Defines the level and extent of SVC obstruction, identifies mass, and evaluates for thrombus. Urgent scan required. Available at all Australian hospital EDs.
Available
Tissue biopsy
CT-guided lung biopsy, bronchoscopy with biopsy, or mediastinoscopy for histological diagnosis. Histology is essential before starting specific therapy unless life-threatening emergency.
Available
Echocardiography
Assesses for pericardial effusion and right heart function.
Available
PET-CT
For staging if malignancy already confirmed. MBS item 61306/61309 restricted benefits.

Management

Mild
Facial swelling, no respiratory compromise
Obtain tissue diagnosis first. Initiate chemotherapy for chemosensitive tumours (SCLC, lymphoma). Consider stenting or radiotherapy if diagnosis established.
Setting: Inpatient, oncology ward
Moderate
Dyspnoea, stridor on exertion
Dexamethasone 4–8 mg IV stat. DVT work-up and anticoagulation if catheter-associated thrombus. Expedite tissue biopsy. Urgent radiotherapy or chemotherapy based on tumour type.
Setting: Inpatient, HDU observation
Severe
Rest dyspnoea, airway compromise, cerebral oedema
Emergency SVC stenting or emergent chemotherapy/radiotherapy without histology. Critical care admission. Consider tissue biopsy after stabilisation.
Setting: ICU/HDU, immediate intervention
💊
Dexamethasone
Corticosteroid — reduces tumour oedema
Adult dose 4–16 mg IV stat then 4–8 mg IV/PO BD until radiotherapy/chemotherapy commenced
PBS status ✔ PBS General Benefit
💊
Enoxaparin
Clexane® · LMWH · Anticoagulant
Adult dose 1 mg/kg SC BD (treatment dose) or 40 mg SC daily (prophylactic). If catheter-associated SVC thrombus confirmed, therapeutic anticoagulation is indicated.
Renal adjustment Reduce to 1 mg/kg OD if CrCl < 30 mL/min; consider unfractionated heparin if CrCl < 15 mL/min
PBS status ✔ PBS General Benefit
ℹ️
SVC stenting: Endovascular stent placement provides rapid symptom relief (within 24–72 h) in > 95% of cases. Stenting is the preferred intervention for life-threatening SVC syndrome. Anticoagulation post-stent is recommended for at least 3–6 months. Interventional radiology referral is essential.

Tumour Lysis Syndrome

Epidemiology & Risk Factors

Tumour lysis syndrome (TLS) is a metabolic emergency caused by rapid release of intracellular contents — potassium, phosphate, nucleic acids (metabolised to uric acid), and cytokines — from lysed malignant cells. It occurs spontaneously or, more commonly, within 1–5 days of initiating cytotoxic chemotherapy. TLS is most frequently associated with haematological malignancies: acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), Burkitt lymphoma, and other high-grade non-Hodgkin lymphomas (NHL). Solid tumours — particularly small cell lung cancer and germ cell tumours — can also cause TLS but less commonly.

Risk Stratification

Low risk
Indolent lymphoma, solid tumours
TLS incidence < 1%. Oral hydration and observation are usually sufficient. Allopurinol if additional risk factors present.
Setting: Outpatient with monitoring
Intermediate risk
DLBCL, ALL, AML with WBC 25–100 × 10⁹/L
TLS incidence 1–5%. IV hydration + allopurinol prophylaxis. Monitor U&Es q6–8h during initial 72 h of therapy.
Setting: Inpatient, regular bloods
High risk
Burkitt, ALL/AML with WBC > 100 × 10⁹/L, high tumour burden
TLS incidence 20–50%. IV hydration + rasburicase (or allopurinol if G6PD deficient contraindication to rasburicase is absent). Intensive monitoring. Consider ICU/HDU admission.
Setting: Inpatient, HDU/ICU monitoring

Cairo-Bishop Diagnostic Criteria

TLS is present if ≥ 2 of the following occur within 3 days before to 7 days after cytotoxic therapy:

  • Uric acid ≥ 476 µmol/L (8 mg/dL) or ≥ 25% increase from baseline
  • Potassium ≥ 6.0 mmol/L or ≥ 25% increase
  • Phosphate ≥ 1.45 mmol/L (adults) or ≥ 2.1 mmol/L (children) or ≥ 25% increase
  • Calcium ≤ 1.75 mmol/L or ≥ 25% decrease

Clinical TLS = laboratory TLS + ≥ 1 of: serum creatinine ≥ 1.5× ULN, cardiac arrhythmia, seizure, or sudden death.

Investigations — Monitoring Schedule

0 h (pre-chemo)
Uric acid, phosphate, potassium, calcium (corrected), creatinine, urea, LDH, ECG. G6PD status if rasburicase considered.
6 h
Repeat K⁺, PO₄³⁻, Ca²⁺, urate, creatinine. Fluid balance assessment.
12 h
Repeat electrolytes. ECG if K⁺ > 5.5 mmol/L.
24 h
Full biochemistry panel. Assess urine output (target > 3 mL/kg/h or 200 mL/h in adults).
48–72 h
Continue q6–8h monitoring. Taper monitoring frequency if stable.

Prophylaxis & Treatment

💊
IV Hydration
0.9% NaCl ± dextrose · Volume expansion
Adult prophylaxis dose 3 L/m²/day (or 200–300 mL/h) 0.9% NaCl IV. Commence 24–48 h pre-chemotherapy.
Adult treatment dose Increase to 200–300 mL/h aiming for urine output > 2–3 mL/kg/h. Add furosemide 20–40 mg IV if fluid overload.
Caution Monitor for fluid overload, especially in patients with cardiac disease or renal impairment.
PBS status ✔ PBS General Benefit
💊
Allopurinol
Zyloprim® · Xanthine oxidase inhibitor
Adult prophylaxis dose 100–300 mg PO daily, starting 2–3 days before chemotherapy. Continue for 7–10 days.
Renal adjustment 100 mg/day if CrCl 10–20 mL/min; 100 mg q48h if CrCl < 10 mL/min
Paediatric dose 10 mg/kg/day PO in 2–3 divided doses (max 300 mg/day)
PBS status ✔ PBS General Benefit
💊
Rasburicase
Fasturtec® · Recombinant urate oxidase
Adult dose 0.2 mg/kg IV infusion over 30 min. Single dose often sufficient; may repeat at 24–48 h if urate remains elevated.
Paediatric dose 0.2 mg/kg IV (same as adult)
Contraindications G6PD deficiency (risk of severe haemolysis). Must check G6PD status before administration, particularly in patients of Mediterranean, African, or Southeast Asian descent.
PBS status 🔒 Authority Required

Management of Specific Derangements

Derangement Immediate Management Definitive Management
Hyperkalaemia (K⁺ > 6.0) Calcium gluconate 10% 10 mL IV over 10 min (cardiac membrane stabiliser). Insulin 10 U + 50 mL 50% dextrose IV. Salbutamol nebuliser 10–20 mg. Calcium resonium 15–30 g PO/PR. Haemodialysis if refractory or K⁺ > 7.0 with ECG changes.
Hyperphosphataemia Phosphate binders: calcium carbonate 500 mg PO TDS with meals or sevelamer 800 mg PO TDS. Restrict dietary phosphate. Haemodialysis if PO₄ > 3.2 mmol/L or symptomatic hypocalcaemia.
Hypocalcaemia Calcium gluconate 10% 10–20 mL IV slowly if symptomatic (tetany, seizures, QT prolongation). Treat underlying hyperphosphataemia. Do NOT give IV calcium unless symptomatic — risk of ectopic calcium phosphate deposition.
Acute kidney injury Optimise hydration. Avoid nephrotoxins. Furosemide if oliguric with fluid overload. Rasburicase if hyperuricaemia is the cause. Haemodialysis/haemofiltration if AKI is refractory (Cr rising, K⁺ uncontrolled, fluid overload).
⚠️
G6PD testing before rasburicase: Rasburicase is contraindicated in G6PD deficiency as it can precipitate severe oxidative haemolysis and methaemoglobinaemia. Test G6PD before administering rasburicase, especially in patients of Mediterranean, African, Middle Eastern, or Southeast Asian ancestry. If G6PD is unknown and rasburicase is urgently needed, use allopurinol as an alternative.

Febrile Neutropenia Management

Epidemiology & Definitions

Febrile neutropenia (FN) is the most common oncological emergency in Australia, accounting for approximately 30,000 hospitalisations annually. It carries an overall mortality rate of 5–10%, with mortality exceeding 30% in patients with documented bacteraemia or septic shock.

Definitions (IDSA/ACSQHC):

  • Fever: Single oral temperature ≥ 38.0 °C, or ≥ 38.3 °C sustained over 1 hour.
  • Neutropenia: Absolute neutrophil count (ANC) < 0.5 × 10⁹/L, or ANC < 1.0 × 10⁹/L with expected decline to < 0.5 × 10⁹/L within 48 h.
  • Profound neutropenia: ANC < 0.1 × 10⁹/L — higher infection risk and broader empiric coverage may be warranted.

Risk Stratification — MASCC Score

Variable Weight
Burden of illness: no or mild symptoms +5
No hypotension (SBP > 90 mmHg) +5
No COPD +4
Solid tumour or no previous fungal infection +4
No dehydration requiring parenteral fluids +3
Outpatient at fever onset +3
Age < 60 years +2

Score ≥ 21 = Low risk (mortality < 5%) — consider oral antibiotics or early discharge with GP follow-up.
Score < 21 = High risk (mortality 9–36%) — inpatient IV antibiotics required.

Investigations

Essential
Blood cultures (2 sets)
One set from each lumen of any indwelling central venous catheter + one peripheral set. Draw before first antibiotic dose. Repeat at 48–72 h if persistent fever.
Essential
FBC with differential, EUC, LFTs, CRP, lactate
Confirm neutrophil count. Elevated lactate (> 2 mmol/L) suggests sepsis. CRP trending is useful for monitoring treatment response.
Available
Urinalysis and urine culture
Always collect — UTI is a common source. Mid-stream or catheter specimen.
Available
Chest X-ray
Even in asymptomatic patients — pulmonary infiltrates may be subtle in neutropenia.
As indicated
CT chest/abdomen/pelvis, sinus CT, wound swabs, stool for C. difficile
If source not identified, or clinical deterioration despite 48–72 h of empiric therapy.

Empirical Antibiotic Therapy

🚨
Time-critical: Empiric IV antibiotics must be administered within 60 minutes of presentation for febrile neutropenia. Delay beyond 1 hour is associated with increased mortality — particularly in patients with haematological malignancies, sepsis, or profound neutropenia.
💊
Piperacillin-Tazobactam
Tazocin® · β-lactam/β-lactamase inhibitor
Adult dose 4.5 g IV every 6 h (8-hourly if CrCl 20–80 mL/min and non-critically ill)
Paediatric dose 90 mg/kg/dose IV every 6 h (max 4.5 g/dose)
Renal adjustment 4.5 g every 8 h if CrCl 20–80 mL/min; 4.5 g every 12 h if CrCl < 20 mL/min
Role First-line empiric monotherapy for febrile neutropenia (eTG 2024)
PBS status ✔ PBS General Benefit
💊
Meropenem
Merem® · Carbapenem
Adult dose 1 g IV every 8 h (2 g every 8 h for Pseudomonas/ICU sepsis)
Indications Penicillin allergy (anaphylaxis), ESBL-colonised patients, clinical deterioration on piperacillin-tazobactam, ICU admission
Renal adjustment 500 mg every 8 h if CrCl 26–50; 500 mg every 12 h if CrCl 10–25
PBS status ✔ PBS General Benefit
💊
Gentamicin
Genta · Aminoglycoside
Adult dose 4–7 mg/kg IV (extended-interval dosing, based on adjusted body weight). Give as adjunct to piperacillin-tazobactam or meropenem if haemodynamically unstable, known MRSA risk, or Gram-negative resistance.
Monitoring Trough level < 1 mg/L. Check level before 2nd dose. Monitor renal function daily.
Renal adjustment Dose by adjusted body weight; extend interval based on levels
PBS status ✔ PBS General Benefit

Addition of Vancomycin — Indications

Add vancomycin IV empirically (do not wait for culture results) if any of the following are present:

  • Suspected catheter-related infection (erythema, tenderness over CVC insertion site)
  • Known MRSA colonisation or prior MRSA infection
  • Skin/soft tissue infection
  • Haemodynamic instability / septic shock
  • Institutional MRSA prevalence > 10%
💊
Vancomycin
Vancocin® · Glycopeptide
Adult dose 25–30 mg/kg IV loading dose (max 2 g), then 15–20 mg/kg IV every 8–12 h. Target trough 15–20 mg/L (serious infections).
Infusion Administer over ≥ 60 min (minimum 10 mg/min) to avoid red man syndrome
Renal adjustment Dose per AUC-guided dosing or trough monitoring. Adjust frequency based on CrCl and levels.
PBS status ✔ PBS General Benefit

Low-Risk Febrile Neutropenia — Oral Therapy Option

✅
Low risk (MASCC ≥ 21): Selected patients with solid tumours, good performance status, no signs of sepsis, and reliable follow-up may be managed with oral antibiotics in a supervised ambulatory setting (hospital-in-the-home or daily review). This approach must be approved by the treating haematologist/oncologist.
💊
Ciprofloxacin + Amoxicillin-Clavulanate
Ciprofloxacin + Augmentin Duo®
Adult dose Ciprofloxacin 500 mg PO BD + Amoxicillin-clavulanate 875/125 mg PO BD
Duration Continue until afebrile ≥ 48 h and ANC > 0.5 × 10⁹/L (minimum 7 days)
PBS status ✔ PBS General Benefit (both agents)

Sepsis / Septic Shock — Escalation

1
Sepsis Six (within 1 hour)
Give oxygen to maintain SpO₂ > 94%. Take blood cultures. Give IV antibiotics (piperacillin-tazobactam + gentamicin ± vancomycin). Give IV crystalloid 500 mL stat bolus. Measure serum lactate. Measure urine output (catheterise if required).
2
Fluid resuscitation
20–30 mL/kg crystalloid bolus. Reassess after each bolus. Target MAP > 65 mmHg. Avoid fluid overload — cancer patients may have cardiac dysfunction from anthracycline therapy.
3
Vasopressors
Noradrenaline 0.1–1 µg/kg/min IV via central line if MAP < 65 mmHg despite adequate fluid resuscitation. ICU/HDU transfer. Early infectious diseases and critical care consultation.
4
G-CSF consideration
Filgrastim (Neupogen®) 5 µg/kg SC daily may be considered in high-risk FN (expected duration of neutropenia > 7 days, pneumonia, hypotension, age > 65, multi-organ dysfunction). NOT routinely recommended for uncomplicated FN.
💊
Filgrastim
Neupogen® · Granulocyte colony-stimulating factor
Adult dose 5 µg/kg SC daily until ANC > 1.0 × 10⁹/L for 2 consecutive days
Paediatric dose 5 µg/kg SC daily (same as adult)
Indication High-risk febrile neutropenia with sepsis, pneumonia, or expected prolonged neutropenia (> 7 days)
PBS status 🔒 Authority Required

Monitoring & Duration of Therapy

  • Daily FBC, EUC, CRP, lactate (if septic).
  • Repeat blood cultures at 48–72 h if initial cultures positive or ongoing fever.
  • Low risk, responding: Switch to oral antibiotics at 48 h if afebrile, clinically improving, and ANC recovering. Total minimum course 7 days or until ANC > 0.5 × 10⁹/L.
  • High risk, culture-negative at 72 h: Continue empiric antibiotics. Reassess source (CT, repeat cultures, consider antifungal if prolonged neutropenia > 7 days and persistent fever).
  • Add antifungal (fluconazole, voriconazole, or caspofungin) if fever persists > 4–7 days on broad-spectrum antibiotics with ongoing profound neutropenia — suspect invasive fungal infection.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health
Cancer incidence & stage
Aboriginal and Torres Strait Islander Australians have a 14% higher cancer mortality rate and are more likely to present with advanced-stage disease. Cancers associated with oncological emergencies (lung, haematological) carry disproportionately higher incidence in Indigenous communities. Late presentation increases the likelihood of presenting with spinal cord compression, SVC syndrome, or advanced tumour burden.
Remote & rural access
Many Indigenous Australians live in remote or very remote areas with limited access to tertiary oncology, radiation oncology, and interventional radiology services. Retrieval and transfer times for spinal cord compression or SVC syndrome can exceed 24 hours from remote communities. The Royal Flying Doctor Service (RFDS) is critical for emergency transfers. Teleoncology services (e.g., Northern Territory, Western Australia) enable initial specialist consultation.
Cultural safety & communication
Language barriers, health literacy, and cultural differences may delay presentation and reduce treatment adherence. Engage Aboriginal Health Workers and Aboriginal Liaison Officers early. Use interpreters for patients whose first language is not English (including Aboriginal English and Kriol). Respect kinship obligations in decision-making — family consensus may be culturally appropriate.
Dialysis & renal comorbidity
Aboriginal and Torres Strait Islander Australians have 6–8 times higher rates of end-stage kidney disease. This has direct implications for TLS management (rasburicase/allopurinol dosing, fluid management, haemodialysis availability), FN (aminoglycoside and vancomycin dosing), and dexamethasone use (hyperglycaemia in diabetic patients).
G6PD prevalence
G6PD deficiency is more prevalent in some Aboriginal and Torres Strait Islander communities. G6PD testing should be prioritised before rasburicase administration. If G6PD testing is unavailable in remote settings, allopurinol is the safer choice for TLS prophylaxis.
Follow-up & continuity
Post-emergency follow-up should involve coordination with local Aboriginal Community Controlled Health Organisations (ACHOs), GPMP/TCA arrangements, and Indigenous-specific cancer support services (e.g., Cancer Council Aboriginal and Torres Strait Islander programmes).

Special Populations

🤰 Pregnancy
Dexamethasone Category A — safe in pregnancy. Used for fetal lung maturation. Can be used in MSCC and SVC syndrome.
Piperacillin-tazobactam Category B1 — generally safe. First-line for FN in pregnancy.
Meropenem Category B2 — use if penicillin allergy or ESBL concern.
Rasburicase Category B3 — limited data. Use only if benefits clearly outweigh risks; discuss with maternal-fetal medicine.
Gentamicin Category D — ototoxicity risk to fetus. Avoid in pregnancy unless no alternative. Monitor levels closely.
Fluoroquinolones (ciprofloxacin) Category D — avoid in pregnancy (cartilage damage risk).
👶 Paediatrics
FN antibiotics Piperacillin-tazobactam 90 mg/kg/dose IV q6h (max 4.5 g). Weight-based dosing essential. Meropenem 20–40 mg/kg/dose IV q8h (max 1 g) for allergy/resistance.
TLS prophylaxis IV hydration 3 L/m²/day (adjust for weight). Allopurinol 10 mg/kg/day PO. Rasburicase 0.2 mg/kg IV (same as adult). Paediatric haematology-oncology team involvement mandatory.
Dexamethasone in children 0.15–0.5 mg/kg/day IV/PO in divided doses for MSCC/SVC. Monitor BGL — children are prone to steroid-induced hyperglycaemia.
G-CSF Filgrastim 5 µg/kg SC daily — same indication as adult. Commonly used in paediatric ALL protocols.
👴 Elderly (≥ 65 years)
Dexamethasone Increased risk of hyperglycaemia, delirium, proximal myopathy. Use lowest effective dose. Aggressive gastroprotection (PPI). Monitor BGL.
Gentamicin Higher nephrotoxicity risk. Use actual body weight for dosing. Monitor levels closely. Extend dosing interval.
Fluid management in TLS Elderly at higher risk of fluid overload and heart failure. Monitor fluid balance aggressively. Lower target urine output may be acceptable. Cardiology consultation if cardiac history.
Goals of care Frailty assessment and advance care planning should be integrated. Some elderly patients with poor performance status may not be candidates for aggressive intervention (e.g., surgical decompression for MSCC). Discuss with patient, family, and treating team.
🫘 Renal Impairment
Piperacillin-tazobactam 4.5 g q8h if CrCl 20–80 mL/min; q12h if CrCl < 20.
Meropenem 500 mg q8h if CrCl 26–50; 500 mg q12h if CrCl 10–25.
Gentamicin Extended interval or avoid if CrCl < 30. Use AUC-guided dosing.
Vancomycin AUC-guided dosing preferred. Loading dose unchanged; maintenance dose and interval adjusted by CrCl and levels.
Allopurinol 100 mg/day if CrCl 10–20; 100 mg q48h if CrCl < 10.
Enoxaparin 1 mg/kg OD (not BD) if CrCl < 30. Consider UFH if CrCl < 15.
🫁 Hepatic Impairment
General principles Most antibiotics used in FN and TLS are safe in hepatic impairment. Dexamethasone has prolonged half-life in severe liver disease — reduce dose and monitor. Allopurinol dose reduction may be required if hepatic dysfunction is severe (max 100 mg/day). Enoxaparin does not require dose adjustment in hepatic impairment but monitor anti-Xa levels if cirrhotic.
🛡️ Immunocompromised
Extended coverage Patients on rituximab, anti-CD20 agents, post-transplant immunosuppression, or with HIV have broader infection risk. Add antifungal (caspofungin 70 mg loading then 50 mg IV daily) if FN persists > 72 h. Consider PJP prophylaxis (co-trimoxazole) in patients with haematological malignancies on prolonged immunosuppression. Add aciclovir if HSV/VZV risk. MRSA, VRE, ESBL colonisation should be checked from prior swab results.

📚 References

  1. 1. National Health and Medical Research Council. Clinical practice guidelines for the management of advanced breast cancer. 2nd ed. Canberra: NHMRC; 2023.
  2. 2. Australian Commission on Safety and Quality in Health Care. National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
  3. 3. Cancer Council Australia. Clinical practice guidelines for the management of lung cancer. Sydney: Cancer Council Australia; 2024. Available from: wiki.cancer.org.au.
  4. 4. Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. 10th ed. East Melbourne: RACGP; 2024.
  5. 5. Australian Institute of Health and Welfare. Cancer in Australia: in brief 2024. Cancer series no. 139. Canberra: AIHW; 2024.
  6. 6. National Cancer Institute. Tumour lysis syndrome. In: PDQ Supportive and Palliative Care Editorial Board. Bethesda, MD: NCI; 2024. Available from: cancer.gov.
  7. 7. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111–v118.
  8. 8. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3–11.
  9. 9. Loeffler JS, Patchell RA. Spinal cord compression. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia: Wolters Kluwer; 2019:2070–2080.
  10. 10. Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome — a proposed classification system and algorithm for management. J Thorac Oncol. 2008;3(8):811–814.
  11. 11. RHDAustralia (at Menzies School of Health Research). Management of rheumatic fever and rheumatic heart disease for Aboriginal and Torres Strait Islander peoples. Darwin: RHDAustralia; 2022.
  12. 12. Australian Indigenous HealthInfoNet. Overview of Aboriginal and Torres Strait Islander health status 2023. Perth: Edith Cowan University; 2024.
  13. 13. Pharmaceutical Benefits Scheme. PBS Schedule. Australian Government Department of Health; 2024. Available from: pbs.gov.au.
  14. 14. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the IDSA. Clin Infect Dis. 2011;52(4):e56–e93.
  15. 15. George B, Mathews V, Srivastava A, Chandy M. Infections among patients with acute leukaemia: a prospective study from a tertiary care centre in India. Hematol Oncol Stem Cell Ther. 2011;4(4):154–161.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).